Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02998671 · ClinicalTrials.gov registry record · Phase 2
Study of Efficacy and Safety of CJM112 in Patients With Moderate to Severe Inflammatory Acne
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT02998671 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 52 participants.
The verdict
NCT02998671, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
The study was designed primarily to assess preliminary efficacy and safety of CJM112 in patients with moderate to severe inflammatory acne and to determine if CJM112 has an adequate clinical profile for further clinical development. In addition, sustainability of response and dose relationship were to be explored.
Interventions
- OTHER Placebo
- BIOLOGICAL CJM112
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2016-12-22 |
| Est. Completion | 2018-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02998671
The ClinicalTrials.gov registry entry for NCT02998671 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02998671 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02998671 about?
NCT02998671 is a clinical study titled "Study of Efficacy and Safety of CJM112 in Patients With Moderate to Severe Inflammatory Acne". The study was designed primarily to assess preliminary efficacy and safety of CJM112 in patients with moderate to severe inflammatory acne and to determine if CJM112 has an adequate clinical profile for further clinical development. In addition, sustainability of response and dose relationship were ...
What is the current status of trial NCT02998671?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2016-12-22. Estimated completion is 2018-08-01.
What interventions are being tested in trial NCT02998671?
The interventions under investigation include: Placebo (OTHER), CJM112 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02998671?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.